<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-102899</identifier>
<setSpec>0210-5705</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Pyogenic liver abscess: clinical presentation and predictors of unfavorable outcome</dc:title>
<dc:description xml:lang="en">Objectives To describe the clinical features of pyogenic liver abscesses (PLA) and identify the factors associated with an unfavorable outcome. Material and methods We performed a retrospective review of the clinical histories of patients with liver abscess (1996-2009), including those that met the diagnostic criteria for PLA. Outcome was classified as favorable or unfavorable (severe sepsis, distant infectious complications, local complications, intensive care unit admission, admission for&gt;30 days, death, readmission).Results There were 54 patients with PLA (65% men), with a mean age of 61 years. Predisposing factors consisted of biliopancreatic disease in 33%, recent admission in 20%, alcoholism in 15%, diabetes mellitus in 15%, a history of gastrointestinal neoplasm in 11% and abdominal surgery in 11%. The cause was cryptogenic in 65%, biliary in 31%, and portal in 4%. Symptoms consisted of fever in 100%, abdominal pain in 65%, vomiting in 37%, enlarged liver in 33%, systemic inflammatory response syndrome in 26%, and jaundice in 9%. Blood and pus cultures were positive in 40% and 65%, respectively. The most frequently isolated microorganisms were E. coli and Streptococcus spp. Percutaneous drainage was performed in 72% (surgical drainage was also performed in 6%), and antibiotic treatment alone was administered in 28%. Outcome was unfavorable in 52% and was associated with greater age (p=0.016), a history of biliopancreatic disease (p=0.007), systemic inflammatory response syndrome at diagnosis (p=0.005), coagulation alterations (p=0.043), aspartate aminotransferase elevation (p=0.033), and biliary etiology (p&lt;0.001).Conclusions PLA developed in patients with comorbidity, although most were cryptogenic. The majority of PLA were resolved with antibiotic therapy and percutaneous drainage, without surgery. Mortality was 9%, but half the patients had unfavorable outcome, associated with biliary etiology and some laboratory alterations (AU)</dc:description>
<dc:creator>López-Cano Gómez, María</dc:creator>
<dc:creator>Laguna Del Estal, Pedro</dc:creator>
<dc:creator>Gil Navarro, Manuel</dc:creator>
<dc:creator>García Montero, Pablo</dc:creator>
<dc:creator>Castañeda Pastor, Ana</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivos Describir clínicamente el absceso hepático piógeno (AHP) e identificar factores asociados a evolución desfavorable. Material y métodos Revisión retrospectiva de historias de pacientes con absceso hepático (1996-2009), incluyendo los que cumplían criterios diagnósticos de AHP. Se clasificaron en evolución favorable y desfavorable (sepsis grave, complicaciones infecciosas a distancia, complicación local, ingreso en cuidados intensivos, ingreso &gt; 30 días, fallecimiento, reingreso).Resultados Se incluyen 54 AHP, 65% hombres, edad media 61 años. Factores predisponentes: enfermedad biliopancreática, 33%; ingreso reciente, 20%; enolismo, 15%; diabetes mellitus, 15%; antecedente de neoplasia digestiva, 11%, y de cirugía abdominal, 11%. Origen: criptogénico, 65%; biliar, 31%; portal, 4%. Sintomatología: fiebre, 100%; dolor abdominal, 65%; vómitos, 37%; hepatomegalia, 33%; síndrome de respuesta inflamatoria sistémica, 26%; ictericia, 9%. Hemocultivos positivos, 40%, y cultivo de pus, 65%. Escherichia coli y Streptococcus spp. fueron los aislamientos más frecuentes. Se efectuó drenaje percutáneo en el 72% (el 6% también quirúrgico), y recibieron solo antibioterapia el 28%. Evolución desfavorable 52%, asociada a mayor edad (p=0,016), antecedentes de enfermedad biliopancreática (p=0,007), síndrome de respuesta inflamatoria sistémica al diagnóstico (p=0,005), alteración de la coagulación (p=0,043), elevación de AST (p=0,033) y etiología biliar (p&lt;0,001). Conclusiones El AHP se desarrolla en pacientes con comorbilidad, si bien más frecuentemente son criptogénicos. La mayoría curan con antibioterapia y drenaje percutáneo, sin cirugía. La mortalidad es del 9%, pero la mitad sigue una evolución desfavorable, que se asocia a la etiología biliar y a determinadas alteraciones analíticas (AU)</dc:description>
<dc:source>Gastroenterol Hepatol;35(4): 229-235, Abr. 2012. tab</dc:source>
<dc:identifier>ibc-102899</dc:identifier>
<dc:title xml:lang="es">Absceso hepático piógeno: presentación clínica y predictores de evolución desfavorable</dc:title>
<dc:subject>^d38603^s22080</dc:subject>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d27990^s22074</dc:subject>
<dc:subject>^d28611</dc:subject>
<dc:subject>^d911^s22073</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d5017^s22012</dc:subject>
<dc:subject>^d13677^s22012</dc:subject>
<dc:subject>^d24572</dc:subject>
<dc:type>article</dc:type>
<dc:date>201204</dc:date>
</metadata>
</record>
</ibecs-document>
